Multidrug-resistant (MDR) Pseudomonas aeruginosa is an important issue for physicians who take care of patients with cystic fibrosis (CF). Here, we review the latest research on how P. aeruginosa infection causes lung function to decline and how several factors contribute to the emergence of antibiotic resistance in P. aeruginosa strains and influence the course of the infection course. However, many aspects of the practical management of patients with CF infected with MDR P. aeruginosa are still to be established. Less is known about the exact role of susceptibility testing in clinical strategies for dealing with resistant infections, and there is an urgent need to find a tool to assist in choosing the best therapeutic strategy for MDR P. aeruginosa infection. One current perception is that the selection of antibiotic therapy according to antibiogram results is an important component of the decision-making process, but other patient factors, such as previous infection history and antibiotic courses, also need to be evaluated. On the basis of the known issues and the best current data on respiratory infections caused by MDR P. aeruginosa, this review provides practical suggestions to optimize the diagnostic and therapeutic management of patients with CF who are infected with these pathogens.

Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis / S. Campana, L. Cariani, V. Carnovale, C. Colombo, M.M. Lleo, V.D. Iula, L. Minicucci, P. Morelli, G. Pizzamiglio, G. Taccetti. - In: INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY. - ISSN 1438-4221. - 307:6(2017 Sep), pp. 353-362. [10.1016/j.ijmm.2017.07.004]

Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis

L. Cariani;C. Colombo;G. Pizzamiglio
;
2017

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa is an important issue for physicians who take care of patients with cystic fibrosis (CF). Here, we review the latest research on how P. aeruginosa infection causes lung function to decline and how several factors contribute to the emergence of antibiotic resistance in P. aeruginosa strains and influence the course of the infection course. However, many aspects of the practical management of patients with CF infected with MDR P. aeruginosa are still to be established. Less is known about the exact role of susceptibility testing in clinical strategies for dealing with resistant infections, and there is an urgent need to find a tool to assist in choosing the best therapeutic strategy for MDR P. aeruginosa infection. One current perception is that the selection of antibiotic therapy according to antibiogram results is an important component of the decision-making process, but other patient factors, such as previous infection history and antibiotic courses, also need to be evaluated. On the basis of the known issues and the best current data on respiratory infections caused by MDR P. aeruginosa, this review provides practical suggestions to optimize the diagnostic and therapeutic management of patients with CF who are infected with these pathogens.
antibiotic therapy; antimicrobial susceptibility testing; cystic fibrosis; lung infection; multidrug resistance; microbiology; microbiology (medical); infectious diseases
Settore MED/38 - Pediatria Generale e Specialistica
set-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
IntJournMedicalMicrobiol_RelevanceMultidrugResistantPseudomonas_2017.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 388.63 kB
Formato Adobe PDF
388.63 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/556394
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 63
social impact